ViroCarb Inc.

ViroCarb Inc.

ViroCarb Inc. ViroCarb Inc. ViroCarb Inc.

An Antiviral Company


Advancing innovative drugs for viral infections with critical unmet therapeutic needs 

image73

About Us

ViroCarb is working towards a cure for viral infections

  

ViroCarb is a science-driven biotech company focused on the development and commercialization of innovative drugs for viral infections with urgent unmet therapeutic needs. 


Our approach of blocking host cell’s processes needed for viral replication overcomes the limitations of current antiviral drug development, directed against viral-encoded targets, caused by extensive viral mutations that limit efficacy and promote drug resistance (e.g. DNA polymerase, reverse transcriptase, protease, and neuraminidase inhibitors). 

Technology

image74

  

We are developing new small molecule scaffolds that disrupt human cell processes hijacked by multiple viruses for replication and colonization. They represent an entirely new drug class with potential activity against a wide range of pathogenic viruses.

 

One of these processes is RNA alternative splicing, required for the expression of specific viral proteins during infection by viruses such as HIV, influenza, Herpes, Adenovirus, Varicella zoster, Papilloma and Hepatitis b. This process, performed by the host cell’s RNA-processing machinery, generates transcripts that encode structural, regulatory and accessory viral proteins. Another process involves the host cell endoplasmic reticulum functions, these cellular functions are co-opted by viruses such as Dengue, West Nile, Hepatitis C and Coronavirus to promote different steps of the viral life cycle including entry, replication, assembly and egress.


These processes are regulated by specific host cell regulatory pathways, and inhibitors of these pathways have significant therapeutic potential. This approach can be applied to the development of novel drugs for the treatment of infections caused by COVID-19, a coronavirus which is the cause of the acute respiratory distress syndrome, currently plaguing the world. 

Pipeline

image75

  

Targeting host functions that regulate viral infections 


Our preclinical drug candidate, "GPS-491", developed in collaboration with leading academics in molecular genetics, medicinal chemistry and functional genomics from the University of Toronto, University of British Columbia and L'Université de Sherbrooke, exhibits broad and potent activity against all HIV subtypes and against HIV clinical strains resistant to current therapies (US Provisional 62/948,672; filed Dec 16, 2019: in-licensed from UofT, UBC & UdeSh). GPS491 has activity against Adenovirus and Herpes simplex and has potential efficacy against other clinically relevant RNA-splicing dependent viruses. GPS-491 shows excellent tolerability and oral bioavailability in pharmacokinetic studies conducted in mice. 



Development of a new class of HIV entry inhibitors 


ViroCarb has identified a novel series of drug like small molecules compounds with anti-HIV activity from more than four million chemical structures screened “In silico” using target-ligand interaction models between the HIV envelope (gp120-V3 loop domain) and the HIV-host cell receptor (glycosphingolipid: globotriaosyl ceramide). Our leading compounds exhibit strong anti-HIV effect on human T cell lines infected with HIV clinical strains (CXCR4 and CCR5-tropic) and multi-drug resistant strains (International WIPO (PCT) patent application, publication date: June 28, 2018, PN 20180179166; Owner: ViroCarb Inc.)

Meet the Team

Mario Huesca, PhD.

Clifford Lingwood, PhD.

Clifford Lingwood, PhD.

image76

  President & Board Director


 Industrial R&D/drug development experience, successful discovery & development of multiple drug candidates


Molecular & Medical Genetics

University of Toronto, Canada

Clifford Lingwood, PhD.

Clifford Lingwood, PhD.

Clifford Lingwood, PhD.

image77

   CSO & Chairman of the Board 


Senior Scientist, the Hospital for Sick Children & 

Professor at the University of Toronto, Canada

Depts. Biochemistry, Lab. Medicine & Pathobiology 


Co-founder of Select Therapeutics 

(successful NASDAQ exit)

Rav Mahal, PhD.

Clifford Lingwood, PhD.

Daniel Mamelak, PhD.

image78

 CBO & Board Director 


Business executive in API, fine chemicals, biotechnology, drug product and CDMO. 


Company Profile

Carbogen Amcis, Patheon, Eurofins CDMO


Organic Chemistry,

University of Salford, UK

Daniel Mamelak, PhD.

Michael Ling, PhD.

Daniel Mamelak, PhD.

image79

  Board Director


 Founder & President, Custom Biologics, Experience building and operating research-based biopharmaceutical companies


Biochemistry

University of Toronto, Canada

Michael Ling, PhD.

Michael Ling, PhD.

Michael Ling, PhD.

image80

   Board Director 


CEO at GeneBio Systems Inc. Executive, Diagnostics-Xpert. Experience in product development 


Biochemistry

University of Guelph, Canada

Advisors & Collaborators

Scientific:


Dr Jean-Phillipe Julien

The Hospital for Sick Children, Univ. of Toronto, Canada Research Chair Structural Immunology


Dr Alan Cochrane

University of Toronto, HIV Molecular Genetics


Dr David Grierson

University of British Columbia, Pharmaceutical Chemistry


Dr Benoit Chabot

Université de Sherbrooke, Canada Research Chair, Functional Genomics


Dr. Sharon Walmsley

Mt. Sinai Hospital-HIV Clinical Trials Coordinator, Order of Canada



Business and Legal:


Dr Dave Valliere

Ted Rogers School of Management, Ryerson


Dr Richard Bozzato

MaRS-DD


Jay Lefton

Fasken Martineau DuMoulin LLP

image81

Investment

image82

Milestones achieved:

  • Assembled a cohesive and innovative group of collaborators and scientific advisors
  • World-class medicinal chemists, molecular pathologists and leaders in legal and business development 
  • Developed, in-licensed platforms of anti-viral small molecules
  • International patent filing
  • IRAP, MITACS, FedDev, SR&ED funding ($357k)



We are seeking ($CAD):


$2.0M bridge funding

· In vivo efficacy studies-Animal models

· Execution of license agreement

· Pre-clinical R&D activities

· Administration, Legal, IP 


$12.0M seed financing

· IND-enabling pre-clinical studies, licensing program

· Preparation of clinical studies

· Operating Cost

Contact Us

image83

  

ViroCarb Inc.

Suite 1801, 1 Yonge Street

Toronto

Ontario

M5E 1W7

Canada



Mario Huesca, PhD.                                        .

President                                              

(647) 772-9437                                              

mario.huesca@virocarb.com   


Rav Mahal, PhD 

Chief Business Officer    

(416) 569-9221

rav.mahal@virocarb.com